GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Jiuzhou Pharmaceutical Co Ltd (SHSE:603456) » Definitions » EBIT

Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) EBIT : ¥1,136 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Zhejiang Jiuzhou Pharmaceutical Co EBIT?

Zhejiang Jiuzhou Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥288 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,136 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zhejiang Jiuzhou Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 was 15.78%. Zhejiang Jiuzhou Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 21.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zhejiang Jiuzhou Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 10.19%.


Zhejiang Jiuzhou Pharmaceutical Co EBIT Historical Data

The historical data trend for Zhejiang Jiuzhou Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Jiuzhou Pharmaceutical Co EBIT Chart

Zhejiang Jiuzhou Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 296.88 493.45 769.61 1,126.20 1,202.38

Zhejiang Jiuzhou Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 354.12 374.46 377.54 96.25 288.11

Competitive Comparison of Zhejiang Jiuzhou Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Jiuzhou Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Jiuzhou Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Jiuzhou Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zhejiang Jiuzhou Pharmaceutical Co's EV-to-EBIT falls into.



Zhejiang Jiuzhou Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,136 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Jiuzhou Pharmaceutical Co  (SHSE:603456) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zhejiang Jiuzhou Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1199.16 * ( 1 - 15.67% )/( (6085.916 + 6733.078)/ 2 )
=1011.251628/6409.497
=15.78 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10851.987 - 1559.644 - ( 3206.427 - max(0, 1656.62 - 6314.388+3206.427))
=6085.916

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12249.806 - 1457.26 - ( 4059.468 - max(0, 2816.696 - 7636.557+4059.468))
=6733.078

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Zhejiang Jiuzhou Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1152.448/( ( (3722.308 + max(1422.164, 0)) + (3802.616 + max(2004.946, 0)) )/ 2 )
=1152.448/( ( 5144.472 + 5807.562 )/ 2 )
=1152.448/5476.017
=21.05 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(962.281 + 1959.411 + 142.549) - (1559.644 + 0 + 82.433)
=1422.164

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1584.336 + 1803.821 + 128.001) - (1457.26 + 0 + 53.952)
=2004.946

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zhejiang Jiuzhou Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=1136.366/11148.098
=10.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Jiuzhou Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Zhejiang Jiuzhou Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Business Description

Traded in Other Exchanges
N/A
Address
99 Waisha Road, Jiaojiang District, Taizhou, Zhejiang, CHN, 318000
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.
Executives
Sha Yu Jie Directors, senior managers
Mei Yi Jiang Director
Li Yuan Qiang senior management
Yang Nong Gang senior management
Directors, senior managers
Huang Min Xia senior management
Wang Bin Directors, senior managers
Dai Yun You senior management
Jiang Zu Lin Directors, senior managers
Guo Zhen Rong senior management
Chen Zhi Hong Directors, senior managers
Xu Jia Jun Supervisors
Hua Li Rong Director
Lin Hui Lu senior management
Zhu Guo Liang Supervisors

Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Headlines

No Headlines